Evidence map›Paper›PMID 40506527›Full record

ArticleJournal of cancer research and clinical oncology2025

Time to breast cancer recurrence and associated predictors in Public Hospitals of Addis Ababa, Central Ethiopia: a retrospective Cohort Study.

Yadessa Chala, Tesfaye Techane, Bonsisa Bekele, Tesfaye Girma, Warati Fekede, Chalchisa Abdeta, Kibiru Mardasa, Tolera Abdeta, Bedada Teshome, Gashaye Atinkut and 3 more

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yadessa ChalaMadda Walabu University Goba Referral Hospital, Goba, Ethiopia.
Tesfaye TechaneDepartment of Oncology, Saint Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Bonsisa BekeleDepartment of Oncology, Saint Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Tesfaye GirmaDepartment of Oncology, Saint Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Warati FekedeDepartment of Public Health, General Surgery, and Internal Medicine, Adama Hospital Medical College, Adama, Ethiopia.
Chalchisa AbdetaEarly Start, School of Education, University of Wollongong, Wollongong, Australia.
Kibiru MardasaDepartment of Public Health, General Surgery, and Internal Medicine, Adama Hospital Medical College, Adama, Ethiopia.
Tolera AbdetaDepartment of Public Health, General Surgery, and Internal Medicine, Adama Hospital Medical College, Adama, Ethiopia.
Bedada TeshomeAdama Public Health Research and Referral Laboratory Center, Adama, Ethiopia.
Gashaye AtinkutDepartment of Public Health, General Surgery, and Internal Medicine, Adama Hospital Medical College, Adama, Ethiopia.
Abdinasir WakoDepartment of Public Health, General Surgery, and Internal Medicine, Adama Hospital Medical College, Adama, Ethiopia.
Mohammed AdemDepartment of Public Health, General Surgery, and Internal Medicine, Adama Hospital Medical College, Adama, Ethiopia.
Alem DeksisaDepartment of Public Health, General Surgery, and Internal Medicine, Adama Hospital Medical College, Adama, Ethiopia. alexdugna@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer recurrence is a significant concern when the disease returns following surgery. The time to recurrence and factors affecting it are not well studied in low-income countries. This study aimed to assess the time to recurrence and predictors of breast cancer among women treated in public hospitals of Addis Ababa, Ethiopia.

methodsRetrospective cohort study was conducted from April 30 to May 30, 2024, among randomly selected 322 recorded cases. The study covered from September 11, 2018, to September 12, 2023. Data were collected by the Kobo toolbox and analyzed by Stata Version 15. The Cox proportional hazard model was used to identify predictor variables, with assumptions checked using the Schoenfeld residual/global test (0.79). Multi-collinearity was checked using the variance inflation factor (3.72). Variables with a P-value < 0.25 in bivariable analysis were entered into the final multivariable analysis. Variables with a P-value < 0.05 at 95% confidence level were considered independent predictors of recurrence.

resultThe recurrence-free survival (RFS) status at the median follow-up time was 87.5%. The incidence rate of breast cancer recurrence was 6.8 per 100 women years (95%CI = 5.34-8.13) follow-up. The 75%RFS time was 44 months (95CI% = 40-48). The proportion of RFS survival at 24, 36, 48, and 60 months was 91.93%, 83.3%, and 67.7%, 61% respectively. Women aged 40 & below (AHR = 3.32; 95%CI 1.80-5.88), Overweight (AHR = 1.95, 95%CI 1.06 -3.59), surgical margin positive (AHR = 2.1; 95%CI 1.20-4.02), axillary node-positive (AHR = 1.98; 95%CI 1.08-3.61) and comorbidity (AHR = 4.45, 95%CI 2.39-8.30) were independent predictors for increased hazard of recurrence.

conclusionThis study confirms a substantial incidence of breast cancer recurrence, with identifiable predictors including comorbidity, age, overweight, positive axillary node status, lymph node involvement, and deep surgical margin. Targeted interventions aimed at improving patient understanding of recurrence risk, promoting adherence to treatment protocols, and fostering healthy lifestyle modifications are crucial for reducing recurrence rates.

Indexed as

Breast NeoplasmsNeoplasm Recurrence, LocalAdultAgedEthiopiaFemaleFollow-Up StudiesHospitals, PublicHumansMiddle AgedPrognosisRetrospective StudiesRisk FactorsTime FactorsBreastCancerEthiopiaPredictorsRecurrence

Identifiers

PMID40506527
PMCPMC12162745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.